Ibandronate Injection (Ibandronate Sodium Hydrate)
Ibandronate Sodium Monohydrate 3.375mg
Injections · Prescription medication
Ilhwa Co., Ltd.
MFDS item code 201803290 · Notified 2018.08.13 · Insurance code 640903671
Treatment of osteoporosis in postmenopausal women
This medication used for the treatment of osteoporosis in postmenopausal women helps to increase bone density and reduce the risk of fractures. Hormonal changes due to menopause can weaken bones, and this medication can prevent and treat such changes to maintain bone health. It helps to prevent bone loss and strengthens bones, which reduces the risk of fractures in daily life. Additionally, it is effective in lowering the incidence of pain and complications associated with osteoporosis. Therefore, it is an important treatment that supports healthy living for postmenopausal women.
Inject 3mg intravenously over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dose adjustment is required. Patients with renal impairment No dose adjustment is required for patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or greater. Use of this medicine is not recommended in patients whose serum creatinine is greater than 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min, as clinical experience in these patients is insufficient. Elderly patients No dose adjustment is required.
Efficacy and safety have not been studied in children aged 18 years or younger.
This medication must be administered intravenously, and great caution should be taken to avoid administering it intra-arterially or around the vein, as this can cause tissue damage. It should not be used in patients who are allergic to this medication or any of its components or in those with untreated hypocalcemia. While using this medication, side effects such as gastritis, diarrhea, abdominal pain, indigestion, nausea, constipation, musculoskeletal pain, arthralgia, myalgia, headache, rash, etc., may occur, so if any unusual symptoms arise, consult healthcare professionals immediately. Especially when this medication is administered for the first time, flu-like symptoms may temporarily occur, which are usually mild and resolve quickly. There is a risk of osteonecrosis of the jaw while receiving this medication, so it is important to undergo an oral examination and plan any dental treatments prior to starting therapy. Additionally, long-term use may lead to atypical fractures of the femur or other bones, so if there is pain in the thigh or groin area, notify the doctor immediately. This medication can temporarily lower serum calcium levels, so pre-existing hypocalcemia or bone and mineral metabolism disorders must be treated before administration, and adequate intake of calcium and vitamin D is important. Women who are pregnant or breastfeeding should avoid using this medication, as its safety has not been established. In cases of overdose, renal and liver function can be affected, so careful monitoring is necessary and appropriate treatment should be received if required. This medication has minimal metabolic interactions with other drugs; however, patients taking medications that can affect kidney function should undergo regular monitoring during treatment. This medication should not be mixed with solutions containing calcium or other intravenous medications and must be administered with the specified solution. After use, do not reuse the injection needle and syringe, and dispose of them securely, keeping them out of reach of children.
Gastritis, diarrhea, abdominal pain, indigestion, nausea, constipation, musculoskeletal pain, joint pain, muscle pain, influenza-like illness, fatigue, headache, rash, bone pain, debility, injection site reaction, phlebitis, thrombophlebitis, hypersensitivity reaction, angioedema, facial swelling, edema, urticaria, osteonecrosis of the jaw and external auditory canal, uveitis, scleritis, episcleritis, anaphylactic reaction, shock, asthma exacerbation, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, atypical femoral fracture, subtrochanteric femoral fracture, dizziness, optic atrophy, lower motor neuron lesions, tremor, unspecified gastrointestinal disorder, benign gastrointestinal neoplasm, toothache, hyperventilation, cough, dyspnea, laryngitis, vaginitis, menopausal symptoms, multiple organ failure, death, insomnia, anxiety, tinnitus, hearing loss, hypothyroidism, lipoma, ocular hemorrhage, heart failure, urination disorders, hematuria, skin desquamation, sensory impairment, acute renal failure
Not everyone experiences these, and they can vary from person to person.
Store this medication in a sealed container to prevent air ingress, and it is recommended to keep it at room temperature between 1 and 30 degrees Celsius. Proper storage will maintain the medication's effectiveness and prevent degradation.
A colorless, transparent solution in a colorless, transparent glass prefilled syringe containing a single-use injection needle.
3 mL x 1 vial
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Ibandronate Sodium Monohydrate 3.375mg
Injections · Prescription medication
Ilhwa Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Jeil Pharmaceutical Co., Ltd.
Ibandronate Sodium Monohydrate 3.375mg
Solution · Prescription medication
Jeil Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Chodang Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Ajou Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Aliko Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Teragen Etex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.